Abstracts tagged "autoantigens and microbiome"

Abstract Number: 949 • 2017 ACR/ARHP Annual Meeting
Sequence Homology and Immune Reactivity between T Cell Epitopes of Related Gut Microbes and Two Novel Autoantigens Provide a Link between Microbial and Host Immunity in Patients with Rheumatoid Arthritis
Annalisa Pianta¹, Sheila Arvikar², Klemen Strle³, Elise E. Drouin¹, Qi Wang⁴, Catherine E. Costello⁴ and Allen C. Steere⁵, ¹Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, BOSTON, MA, ³Department of Immunology and Inflammatory Diseases, Massachusetts General Hospital, BOSTON, MA, ⁴Center for Biomedical Mass Spectrometry, Boston University School of Medicine, Boston, MA, ⁵Center for Immunolgy and Inflammatory Diseases, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: It has been proposed that immunological triggers at mucosal sites, such as the gut microbiota, may promote autoimmunity affecting joints in patients with rheumatoid…
Abstract Number: 1 • 2014 ACR/ARHP Annual Meeting
Lymphocyte Proliferation to a Cross-Reactive Gut Commensal Candidate in Antiphospholipid Syndrome
William Ruff¹, Silvio M. Vieira², Cassyanne Aguiar^3,4, John Sterpka², Andrew Goodman⁵, Doruk Erkan^3,6 and Martin Kriegel^1,7, ¹Immunobiology, Yale School of Medicine, New Haven, CT, ²Yale School of Medicine, New Haven, CT, ³New York Presbyterian/Weill Cornell Medical Center, New York, NY, ⁴Pediatric Rheumatology, Hospital for Special Surgery, New York, NY, ⁵Microbial Pathogenesis, Yale School of Medicine, Microbial Diversity Institute, New Haven, CT, ⁶Rheumatology, Hospital for Special Surgery, New York, NY, ⁷Medicine, Section of Rheumatology, Yale School of Medicine, New Haven, CT
Background/Purpose: Antiphospholipid syndrome (APS) is an autoimmune clotting disorder of unknown etiology targeting a major autoantigen, β2-glycoprotein I (β2GPI). Infectious triggers have been implicated in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].